Navigation Links
China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent
Date:4/3/2008

BEIJING, April 3, 2008 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products and high intensity focused ultrasound tumor therapy systems, today announced the completion of development of the Prostate Cancer FISH Detection Kit (the "Kit"), a prostate cancer-specific molecular diagnostic test based on the Fluorescent in situ Hybridization ("FISH") technology. The Company expects to launch the Kit in July 2008.

The Kit is designed to detect TMPRSS2 and ETS gene fusions in prostate pathological tissues. Dysregulation of ETS family members through fusions with TMPRSS2 are implicated as cancer-causing gene rearrangements in prostate cancer, which can aid in the detection of early prostate cancer. The Kit consists of three dual-color probe sets, namely TMPRSS2/ETV1 probes, TMPRSS2/ERG probes and TMPRSS2/ETV4 probes. Studies have shown that TMPRSS2/ETS gene fusions occur in approximately 80 percent of prostate cancer cases, indicating that the application of TMPRSS2/ETS gene fusions as specific biomarkers can significantly increase the sensitivity for prostate cancer diagnosis. In addition, it has been reported that the TMPRSS2/ERG fusion may have prognostic significance.

"The successful development of the Kit is a milestone in expanding our FISH reagent portfolio, which represents the first significant product developed by our researchers since the FISH acquisition in 2007," said Mr. Xiaodong Wu, Chairman and CEO of the Company. "Our FISH business has become an important growth driver of the Company and we believe the continual launch of new FISH reagents with huge potential of diagnostic application will drive the growth of our recurring reagent business rapidly."

Prostate cancer is one of the most frequent cancers among men in China and many other countries. In China, prostate-related diseases affect about 60-70% of men over 60 years of age of which the population is about 80 million. Among them, patients with prostate enlargement who need surgical therapy have the opportunity to benefit from the use of the Kit to resolve the diagnosis of prostate cancer.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com .

For more information, please contact:

China Medical Technologies, Inc.

Sam Tsang

Tel: +86-10-6530-8833

Email: IR@chinameditech.com


'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results
2. China Shenghuo Pharmaceutical Holdings, Inc. to Present at Brean Murray Carret & Co. Mainland China Investor Tour
3. China Nepstar Chain Drugstore to Accept TransCard at Shenzhen Outlets
4. China Bionanometer Industries (CBIU) Describes their Current Production Capacity and Product Lines
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. China Shenghuo Reports Full Year 2007 Financial Results
7. China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results
8. China Medicine Corporation to Present at Brean Murray Carret & Co. Mainland China Investor Tour
9. China Yingxia International, Inc. Announces Record Fourth Quarter and Year 2007 Results
10. China Yingxia International Announces Soybean Milk Production Lines Acquisition
11. Cells from the Research Institute of the MUHC on the road to China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... States of America (PRWEB) , ... May 28, 2016 , ... ... SuperCloset knows all too well the day to day issues, struggles and obstacles ... military. The Helping Veterans Grow Project provides active or retired military veteran(s) with ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the Multiple ... The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the ... United Kingdom came together to explore the many pathways individuals use to get into and ...
(Date:5/27/2016)... ... ... Southland Log Homes , designer and manufacturer of America’s Favorite Log ... be found on its website at SouthlandLogHomes.com. , The designs of the wood ... craftsmanship of timber post and beam construction. The result is a barn that ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... An ... returns for a third time to shed lights on the variety of topics detailing ... inspirational stories, “Nurse Appreciation” tackles why this career has gone from being in a ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational ... by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also ... advocates, associations and industry leaders such as Bioness. , As patients feel ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 31, 2016 RnRMarketResearch.com adds "Asthma ... comparative analysis of Asthma therapy at various stages, therapeutics ... of administration (RoA) and molecule type, along with latest ... reviews key players involved in the therapeutic development for ... Complete report on H1 2016 pipeline review ...
(Date:5/30/2016)... 30, 2016 On 28 May, 194 ... by 2030. At the 69 th World Health Assembly, ... Hepatitis Strategy, signalling the greatest global commitment in viral hepatitis ... eliminating hepatitis B and C by 2030 and includes a ... reduce annual deaths by 65% and increase treatment to 80%, ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( NASDAQ: DRIO ... that the Company,s Chief Financial Officer, Zvi Ben-David ... 1-2 in New York, NY and ... Los Angeles, CA. During his ... including the U.S. FDA Clearance and commercial launch of the ...
Breaking Medicine Technology: